Last synced on 30 May 2025 at 11:05 pm

Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System

Page Type
Product Code
Definition
A next generation sequencing (NGS) oncology panel is a device used for the qualitative detection of germline or somatic variants in one or more cancer-related genes. The device is intended to be used on DNA or RNA isolated from human clinical specimens.
Physical State
Multiplex, high-throughput next generation sequencing-based test system. The device may include hybridization- or amplification-based capture methods for library construction. Test consists of reagents, instrumentation, software, and instructions needed to perform the test method.
Technical Method
The assay uses next generation sequencing technology to sequence and identify nucleic acid variants located in specified genes associated with clinical cancer specimens. Variants are identified by comparison to a specified reference sequence.
Target Area
Human clinical specimens
Review Panel
Pathology
Submission Type
PMA
Device Classification
Class 3
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

No Linked CFR Text

The FDA has not linked product code PQP to any particular section of the CFR (Code of Federal Regulations). There are multiple reasons why this might be the case:

  • The product code was created for a class III submission that does not follow the normal PMN or PMA path - e.g., for a device that falls under HDE (Humanitarian Device Exemption) or EUA (Emergency Use Authorization).
  • The FDA has generated the product code for an existing Class III device, as a result of a PMA supplement that modifies the device in a way that it can't fit under the existing product code originally assigned
  • The product code was created for internal use at the FDA, and not for classification or regulatory-related purposes.

Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System

Page Type
Product Code
Definition
A next generation sequencing (NGS) oncology panel is a device used for the qualitative detection of germline or somatic variants in one or more cancer-related genes. The device is intended to be used on DNA or RNA isolated from human clinical specimens.
Physical State
Multiplex, high-throughput next generation sequencing-based test system. The device may include hybridization- or amplification-based capture methods for library construction. Test consists of reagents, instrumentation, software, and instructions needed to perform the test method.
Technical Method
The assay uses next generation sequencing technology to sequence and identify nucleic acid variants located in specified genes associated with clinical cancer specimens. Variants are identified by comparison to a specified reference sequence.
Target Area
Human clinical specimens
Review Panel
Pathology
Submission Type
PMA
Device Classification
Class 3
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

No Linked CFR Text

The FDA has not linked product code PQP to any particular section of the CFR (Code of Federal Regulations). There are multiple reasons why this might be the case:

  • The product code was created for a class III submission that does not follow the normal PMN or PMA path - e.g., for a device that falls under HDE (Humanitarian Device Exemption) or EUA (Emergency Use Authorization).
  • The FDA has generated the product code for an existing Class III device, as a result of a PMA supplement that modifies the device in a way that it can't fit under the existing product code originally assigned
  • The product code was created for internal use at the FDA, and not for classification or regulatory-related purposes.